ENDPOINTS

Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drug

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed an early-phase study, and the biotech is planning to apply ...

Mar 17, 2025 - 12:04
 0
Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drug
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed an early-phase study, and the biotech is planning to apply ...
Read More

Tags:

Previous Article

How climate change could make Earth's space junk problem even worse

Next Article

HC Bioscience, a tRNA biotech backed by ARCH and Takeda, shuts down

Related Posts

FDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi

FDA approves Ono’s rare joint tumor drug, setting up ba...

Feb 18, 2025  0

Ono licenses rare blood disease drug from Ionis for $280M upfront

Ono licenses rare blood disease drug from Ionis for $28...

Mar 12, 2025  0

CBER's deputy director departs as staff shakeup continues

CBER's deputy director departs as staff shakeup continues

Feb 21, 2025  0